Mobocertinib: Mechanism of action, clinical, and translational science

• প্রধান লেখক: Michael J. Hanley (লেখক), D. Ross Camidge (লেখক), Robert J. Fram (লেখক), Neeraj Gupta (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wiley, 2024-03-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations...